GALECTIN THERAPEUTICS INC — Director's Dealing 2026

Jan 21, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2026-01-16

Reporting Person: Jamil Khurram (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-16	Stock option (right to buy)	$3.04	A	65000	Acquired	2036-01-16	Common Stock (65000)	Direct
2026-01-16	Restricted Stock Unit	$	A	100000	Acquired		Common Stock (100000)	Direct

Footnotes

F1: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.

F3: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.

F4: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.